CA-INGRAM-MICRO-CLOUD
31.3.2020 15:02:06 CEST | Business Wire | Press release
Ingram Micro Cloud announced today information and programs to assist resellers in helping their customers easily and successfully navigate the recent rebranding of Microsoft Inc.’s Office 365 SMB subscriptions.
Ingram Micro Cloud is extending two new incentives to our partners: 30 days free for new Microsoft 365 seats purchased through Cloud Marketplace (in select markets) as well as free email and data migration to Microsoft 365.
Microsoft 365 is the productivity cloud designed to help users achieve what matters, in work and life, with best-in-class Office apps, intelligent cloud services and advanced security. Microsoft Teams will continue to be included, providing remote working capabilities that are especially important in today’s environment. Office 365 SMB business plans will be renamed Microsoft 365 business plans effective April 21, 2020. The updated name for Office 365 Business Essentials, Office 365 Business Premium, Microsoft 365 Business, and Office 365 Business will also be reflected on Ingram Micro Cloud Marketplace effective April 21, 2020. We encourage all partners to begin using the new naming conventions by that time.
Developing a Modern Workplace practice has become ubiquitous with the new Microsoft 365 business plans. For partners looking to accelerate their cloud journey leading with Microsoft 365, our Modern Workplace Accelerate program delivers exclusive services, promotions and offerings to help build a successful practice. Program details and registration available here .
“Moving to the cloud requires specific tools and skill-sets,” says Tim Fitzgerald, vice president of channel sales at Ingram Micro Cloud. “Ingram Micro Cloud is here to help partners accelerate through that journey and we believe there’s no better time than now to lead with Microsoft 365.”
In addition, Ingram Micro Cloud will also extend its Free Migration Offer through June 30, 2020. The offer allows channel partners to access a free FLY migration license for smooth data migration to the cloud when purchasing net new seats of Microsoft 365 Business Basic, Microsoft 365 Business Standard (Office 365 Business Essentials, Office 365 Business Premium), Microsoft 365 Business Premium (Microsoft 365 Business), Microsoft 365 E3, and E5. Offer details are available here .
About Ingram Micro Cloud
Ingram Micro Cloud brings together innovators and problem solvers to help the world accomplish more. It facilitates and manages the cloud’s complex digital value chain—all powered by CloudBlue technology. Ingram Micro Cloud operates in 64 countries with over 55,000 reseller partners, and its Cloud Marketplace serves 6.5 million seats, offering more than 120 cloud solutions. With unmatched global reach, easy access to automated go-to-market and integration tools, deep technical expertise, and a curated selection of scalable SaaS and IaaS solutions, Ingram Micro Cloud helps vendors, resellers and managed service providers by offering More as a Service. Detailed information is available at www.IngramMicroCloud.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200331005260/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 10:08:00 CET | Press release
Vonage verified Postman workspace extends reach by 40+ million developers; MCP servers and Startup Program among resources designed to further accelerate time-to-value for developers and enterprises Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network API
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom